BioSpace News Archive

MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase 3 clinical study in the treatment of patients with Alzheimer’s disease.

FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will expand its testing efforts for the novel coronavirus, or COVID-19. The Company was previously testing in Germany’s Mecklenburg-Western Pomerania region, and will now be offeri

Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced the closing of its initial public offering of 4,025,000 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 525,000 additional shares. The gross proceeds to the Company, before underwriting discounts and commissions and fees and expenses, are approximately $64

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc (“Zylö”). Mr. Robb Knie, Chief Executive Officer of Hoth,

Ivy Rehab Physical Therapy, a national leader in outpatient physical, occupational, and speech therapy services, is proud to share that it has expanded in-network coverage with Aetna.

New research from Exact Sciences Corp. (NASDAQ: EXAS) uses real-world-adjusted adherence rates in a colorectal cancer microsimulation, the Colorectal Cancer and Adenoma Incidence and Mortality model (CRC-AIM), to reinforce the value of Cologuard (mt-sDNA) as an effective colorectal cancer screening test.

Funds to Support Commercial Launch and Post-Market Clinical Studies of Tapestry® for serious tendon and ligament injuries.

caresyntax to Make Periop Insight Platform Available Free of Charge to Hospitals and ASCs as part of the

Tangen Biosciences, Inc., an innovative developer of rapid, portable, and Point-of-Care diagnostics, today announced that the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded TangenTM the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to rapidly develop infectious disease tests.